nodes	percent_of_prediction	percent_of_DWPC	metapath
Phenazopyridine—Digestion impaired—Fludarabine—lymphatic system cancer	0.0714	0.0714	CcSEcCtD
Phenazopyridine—Meningitis aseptic—Methotrexate—lymphatic system cancer	0.0601	0.0601	CcSEcCtD
Phenazopyridine—Haemolytic anaemia—Mechlorethamine—lymphatic system cancer	0.0592	0.0592	CcSEcCtD
Phenazopyridine—Haemolytic anaemia—Teniposide—lymphatic system cancer	0.0437	0.0437	CcSEcCtD
Phenazopyridine—Jaundice—Mechlorethamine—lymphatic system cancer	0.0402	0.0402	CcSEcCtD
Phenazopyridine—Visual disturbance—Fludarabine—lymphatic system cancer	0.0366	0.0366	CcSEcCtD
Phenazopyridine—Visual impairment—Fludarabine—lymphatic system cancer	0.0231	0.0231	CcSEcCtD
Phenazopyridine—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.0194	0.0194	CcSEcCtD
Phenazopyridine—Pruritus—Mechlorethamine—lymphatic system cancer	0.0186	0.0186	CcSEcCtD
Phenazopyridine—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.018	0.018	CcSEcCtD
Phenazopyridine—Vomiting—Mechlorethamine—lymphatic system cancer	0.0167	0.0167	CcSEcCtD
Phenazopyridine—Rash—Mechlorethamine—lymphatic system cancer	0.0166	0.0166	CcSEcCtD
Phenazopyridine—Dermatitis—Mechlorethamine—lymphatic system cancer	0.0166	0.0166	CcSEcCtD
Phenazopyridine—Nausea—Mechlorethamine—lymphatic system cancer	0.0156	0.0156	CcSEcCtD
Phenazopyridine—Jaundice—Mitoxantrone—lymphatic system cancer	0.0155	0.0155	CcSEcCtD
Phenazopyridine—Dyspepsia—Fludarabine—lymphatic system cancer	0.015	0.015	CcSEcCtD
Phenazopyridine—Visual impairment—Carmustine—lymphatic system cancer	0.0148	0.0148	CcSEcCtD
Phenazopyridine—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.0147	0.0147	CcSEcCtD
Phenazopyridine—Hypersensitivity—Teniposide—lymphatic system cancer	0.0143	0.0143	CcSEcCtD
Phenazopyridine—Hepatitis—Mitoxantrone—lymphatic system cancer	0.0143	0.0143	CcSEcCtD
Phenazopyridine—Pruritus—Teniposide—lymphatic system cancer	0.0137	0.0137	CcSEcCtD
Phenazopyridine—Diarrhoea—Teniposide—lymphatic system cancer	0.0133	0.0133	CcSEcCtD
Phenazopyridine—Hypersensitivity—Fludarabine—lymphatic system cancer	0.0125	0.0125	CcSEcCtD
Phenazopyridine—Vomiting—Teniposide—lymphatic system cancer	0.0123	0.0123	CcSEcCtD
Phenazopyridine—Rash—Teniposide—lymphatic system cancer	0.0122	0.0122	CcSEcCtD
Phenazopyridine—Dermatitis—Teniposide—lymphatic system cancer	0.0122	0.0122	CcSEcCtD
Phenazopyridine—Headache—Teniposide—lymphatic system cancer	0.0121	0.0121	CcSEcCtD
Phenazopyridine—Pruritus—Fludarabine—lymphatic system cancer	0.012	0.012	CcSEcCtD
Phenazopyridine—Diarrhoea—Fludarabine—lymphatic system cancer	0.0117	0.0117	CcSEcCtD
Phenazopyridine—Nausea—Teniposide—lymphatic system cancer	0.0115	0.0115	CcSEcCtD
Phenazopyridine—Visual disturbance—Methotrexate—lymphatic system cancer	0.0108	0.0108	CcSEcCtD
Phenazopyridine—Vomiting—Fludarabine—lymphatic system cancer	0.0108	0.0108	CcSEcCtD
Phenazopyridine—Rash—Fludarabine—lymphatic system cancer	0.0107	0.0107	CcSEcCtD
Phenazopyridine—Dermatitis—Fludarabine—lymphatic system cancer	0.0107	0.0107	CcSEcCtD
Phenazopyridine—Headache—Fludarabine—lymphatic system cancer	0.0107	0.0107	CcSEcCtD
Phenazopyridine—Nausea—Fludarabine—lymphatic system cancer	0.0101	0.0101	CcSEcCtD
Phenazopyridine—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00941	0.00941	CcSEcCtD
Phenazopyridine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.0092	0.0092	CcSEcCtD
Phenazopyridine—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00898	0.00898	CcSEcCtD
Phenazopyridine—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00892	0.00892	CcSEcCtD
Phenazopyridine—Pruritus—Bleomycin—lymphatic system cancer	0.00883	0.00883	CcSEcCtD
Phenazopyridine—Hypersensitivity—Carmustine—lymphatic system cancer	0.00803	0.00803	CcSEcCtD
Phenazopyridine—Vomiting—Bleomycin—lymphatic system cancer	0.00794	0.00794	CcSEcCtD
Phenazopyridine—Rash—Bleomycin—lymphatic system cancer	0.00787	0.00787	CcSEcCtD
Phenazopyridine—Dermatitis—Bleomycin—lymphatic system cancer	0.00787	0.00787	CcSEcCtD
Phenazopyridine—Hypersensitivity—Vincristine—lymphatic system cancer	0.00767	0.00767	CcSEcCtD
Phenazopyridine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00747	0.00747	CcSEcCtD
Phenazopyridine—Diarrhoea—Carmustine—lymphatic system cancer	0.00746	0.00746	CcSEcCtD
Phenazopyridine—Nausea—Bleomycin—lymphatic system cancer	0.00742	0.00742	CcSEcCtD
Phenazopyridine—Diarrhoea—Vincristine—lymphatic system cancer	0.00712	0.00712	CcSEcCtD
Phenazopyridine—Hepatitis—Methotrexate—lymphatic system cancer	0.00711	0.00711	CcSEcCtD
Phenazopyridine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00693	0.00693	CcSEcCtD
Phenazopyridine—Vomiting—Carmustine—lymphatic system cancer	0.00693	0.00693	CcSEcCtD
Phenazopyridine—Rash—Carmustine—lymphatic system cancer	0.00687	0.00687	CcSEcCtD
Phenazopyridine—Dermatitis—Carmustine—lymphatic system cancer	0.00687	0.00687	CcSEcCtD
Phenazopyridine—Visual impairment—Methotrexate—lymphatic system cancer	0.00685	0.00685	CcSEcCtD
Phenazopyridine—Headache—Carmustine—lymphatic system cancer	0.00683	0.00683	CcSEcCtD
Phenazopyridine—Vomiting—Vincristine—lymphatic system cancer	0.00662	0.00662	CcSEcCtD
Phenazopyridine—Rash—Vincristine—lymphatic system cancer	0.00656	0.00656	CcSEcCtD
Phenazopyridine—Dermatitis—Vincristine—lymphatic system cancer	0.00655	0.00655	CcSEcCtD
Phenazopyridine—Headache—Vincristine—lymphatic system cancer	0.00652	0.00652	CcSEcCtD
Phenazopyridine—Nausea—Carmustine—lymphatic system cancer	0.00647	0.00647	CcSEcCtD
Phenazopyridine—Vomiting—Mitoxantrone—lymphatic system cancer	0.00644	0.00644	CcSEcCtD
Phenazopyridine—Rash—Mitoxantrone—lymphatic system cancer	0.00639	0.00639	CcSEcCtD
Phenazopyridine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00638	0.00638	CcSEcCtD
Phenazopyridine—Headache—Mitoxantrone—lymphatic system cancer	0.00635	0.00635	CcSEcCtD
Phenazopyridine—Nausea—Vincristine—lymphatic system cancer	0.00618	0.00618	CcSEcCtD
Phenazopyridine—Nausea—Mitoxantrone—lymphatic system cancer	0.00602	0.00602	CcSEcCtD
Phenazopyridine—Dyspepsia—Methotrexate—lymphatic system cancer	0.00444	0.00444	CcSEcCtD
Phenazopyridine—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00436	0.00436	CcSEcCtD
Phenazopyridine—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00372	0.00372	CcSEcCtD
Phenazopyridine—Pruritus—Methotrexate—lymphatic system cancer	0.00357	0.00357	CcSEcCtD
Phenazopyridine—Diarrhoea—Methotrexate—lymphatic system cancer	0.00345	0.00345	CcSEcCtD
Phenazopyridine—Vomiting—Methotrexate—lymphatic system cancer	0.00321	0.00321	CcSEcCtD
Phenazopyridine—Rash—Methotrexate—lymphatic system cancer	0.00318	0.00318	CcSEcCtD
Phenazopyridine—Dermatitis—Methotrexate—lymphatic system cancer	0.00318	0.00318	CcSEcCtD
Phenazopyridine—Headache—Methotrexate—lymphatic system cancer	0.00316	0.00316	CcSEcCtD
Phenazopyridine—Nausea—Methotrexate—lymphatic system cancer	0.003	0.003	CcSEcCtD
